Abbisko Enrolls First Patient in Phase II Study for ABSK091 in Urothelial Carcinoma
China-based Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the enrollment of the first patient...
HKG: 2256
Abbisko’s ABSK021 Gets CDE Approval for Phase III Study in Giant Cell Tumor of Tendon Sheath
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval...
Abbisko Therapeutics Doses First Patient in Phase I Study of ABSK043
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that the first patient has...
Abbisko Therapeutics’ ABSK021 Receives BTD for Giant Cell Tumor Treatment
Shanghai-based Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that its Category 1 drug ABSK021 has...
Abbisko Therapeutics Doses First Patient in ABSK061 Phase I Study for Solid Tumors
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the first patient dosing in a...